Among obese teens, most rapid weight gain happened in childhood between ages 2 and 6

Additional focus on lifestyle management, self-management education and support emphasized

Lorcaserin reduces risk for diabetes for those with prediabetes, without diabetes; reduces HbA1c

Lixisenatide reduces progression of urinary albumin-creatinine ratio in patients with macroalbuminuria

Recommendations address screening, treatment approaches and emphasize shared decision making

Despite having been withdrawn, albiglutide is superior to placebo for reducing cardiovascular events

High HbA1c levels within two years of diagnosis predict increased risk for psychiatric diagnoses

Better glycemic control, reduced hypoglycemia risk for T1DM patients with suboptimal glycemic control

Here are what the editors at HealthDay consider to be the most important developments in Diabetes & Endocrinology for September 2018. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.Increased Cardiovascular …

Five clusters of T2DM loci and traits, each with distinct tissue-specific enhancer enrichment, identified